7-Hydroxystaurosporine (BioDeep_00000175103)

   

human metabolite blood metabolite


代谢物信息卡片


18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8,10,12,14(28),15(19),20(27),21(26),22,24-nonaen-16-one

化学式: C28H26N4O4 (482.19539560000004)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 94.44%

分子结构信息

SMILES: CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C(NC6=O)O)NC)OC
InChI: InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)

描述信息

D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents

同义名列表

7 个代谢物同义名

18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8,10,12,14(28),15(19),20(27),21(26),22,24-nonaen-16-one; 7-Hydroxy-staurosporine; 7-Hydroxystaurosporine; CID 4616292; UCN-01; UCN 01; UCN 02



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Angela Serra, Michele Fratello, Antonio Federico, Ravi Ojha, Riccardo Provenzani, Ervin Tasnadi, Luca Cattelani, Giusy Del Giudice, Pia A S Kinaret, Laura A Saarimäki, Alisa Pavel, Suvi Kuivanen, Vincenzo Cerullo, Olli Vapalahti, Peter Horvath, Antonio Di Lieto, Jari Yli-Kauhaluoma, Giuseppe Balistreri, Dario Greco. Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. Briefings in bioinformatics. 2022 01; 23(1):. doi: 10.1093/bib/bbab507. [PMID: 34962256]
  • Erik J B Landin, Christopher Williams, Sara A Ryan, Alice Bochel, Nahida Akter, Christina Redfield, Richard B Sessions, Neesha Dedi, Richard J Taylor, Matthew P Crump. The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01. The Journal of biological chemistry. 2021 12; 297(6):101392. doi: 10.1016/j.jbc.2021.101392. [PMID: 34758357]
  • Zhiqing Huang, Eiji Kondoh, Zachary R Visco, Tsukasa Baba, Noriomi Matsumura, Emma Dolan, Regina S Whitaker, Ikuo Konishi, Shingo Fujii, Andrew Berchuck, Susan K Murphy. Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance. Molecular cancer therapeutics. 2021 01; 20(1):85-95. doi: 10.1158/1535-7163.mct-20-0119. [PMID: 33037137]
  • Kotohiko Kimura, Ru Chih C Huang. Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01. PloS one. 2016; 11(2):e0148685. doi: 10.1371/journal.pone.0148685. [PMID: 26886430]
  • Aakanchha Jain, Sourabh Jain, Richa Jain, Dharm Veer Kohli. Coated chitosan nanoparticles encapsulating caspase 3 activator for effective treatment of colorectral cancer. Drug delivery and translational research. 2015 Dec; 5(6):596-610. doi: 10.1007/s13346-015-0255-x. [PMID: 26334865]
  • M Signore, F Pelacchi, S di Martino, D Runci, M Biffoni, S Giannetti, L Morgante, M De Majo, E F Petricoin, L Stancato, L M Larocca, R De Maria, R Pallini, L Ricci-Vitiani. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell death & disease. 2014 May; 5(?):e1223. doi: 10.1038/cddis.2014.188. [PMID: 24810059]
  • Eiji Kondoh, Seiichi Mori, Ken Yamaguchi, Tsukasa Baba, Noriomi Matsumura, J Cory Barnett, Regina S Whitaker, Ikuo Konishi, Shingo Fujii, Andrew Berchuck, Susan K Murphy. Targeting slow-proliferating ovarian cancer cells. International journal of cancer. 2010 May; 126(10):2448-56. doi: 10.1002/ijc.24919. [PMID: 19795452]
  • Ulrich Bork, Wing-Kee Lee, Anna Kuchler, Thomas Dittmar, Frank Thévenod. Cadmium-induced DNA damage triggers G(2)/M arrest via chk1/2 and cdc2 in p53-deficient kidney proximal tubule cells. American journal of physiology. Renal physiology. 2010 Feb; 298(2):F255-65. doi: 10.1152/ajprenal.00273.2009. [PMID: 19923412]
  • Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, William D Figg, Giovanni Melillo, Janet Dancey, Edward A Sausville, Barbara A Conley, Anthony J Murgo, James H Doroshow. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer chemotherapy and pharmacology. 2010 Jan; 65(2):383-9. doi: 10.1007/s00280-009-1154-y. [PMID: 19894051]
  • Daman Kumari, Valentina Somma, Asako J Nakamura, William M Bonner, Ettoré D'Ambrosio, Karen Usdin. The role of DNA damage response pathways in chromosome fragility in Fragile X syndrome. Nucleic acids research. 2009 Jul; 37(13):4385-92. doi: 10.1093/nar/gkp391. [PMID: 19465392]
  • Masahiro Yamauchi, Hiroko Kusano, Etsuko Saito, Masayuki Abe, Kyoko Tsutsumi, Yoichi Uosaki, Masashi Nakakura, Yasuki Kato, Noboru Aoki. Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size. International journal of pharmaceutics. 2008 Mar; 351(1-2):250-8. doi: 10.1016/j.ijpharm.2007.08.021. [PMID: 17904317]
  • Raymond P Perez, Lionel D Lewis, Andrew P Beelen, Anthony J Olszanski, Nicholas Johnston, C Harker Rhodes, Bernard Beaulieu, Marc S Ernstoff, Alan Eastman. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec; 12(23):7079-85. doi: 10.1158/1078-0432.ccr-06-0197. [PMID: 17145831]
  • Huadong Tang, Michael Mayersohn. On the observed large interspecies overprediction of human clearance ('vertical allometry') of UCN-01: further support for a proposed model based on plasma protein binding. Journal of clinical pharmacology. 2006 Apr; 46(4):398-400. doi: 10.1177/0091270005285457. [PMID: 16554445]
  • Masahiro Yamauchi, Hiroko Kusano, Masashi Nakakura, Yasuki Kato. Reducing the impact of binding of UCN-01 to human alpha1-acid glycoprotein by encapsulation in liposomes. Biological & pharmaceutical bulletin. 2005 Jul; 28(7):1259-64. doi: 10.1248/bpb.28.1259. [PMID: 15997110]
  • Primo N Lara, Philip C Mack, Timothy Synold, Paul Frankel, Jeff Longmate, Paul H Gumerlock, James H Doroshow, David R Gandara. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jun; 11(12):4444-50. doi: 10.1158/1078-0432.ccr-04-2602. [PMID: 15958629]
  • Eiichi Fuse, Takashi Kuwabara, Alex Sparreboom, Edward A Sausville, William D Figg. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. Journal of clinical pharmacology. 2005 Apr; 45(4):394-403. doi: 10.1177/0091270005274549. [PMID: 15778420]
  • Jeremy Kortmansky, Manish A Shah, Andreas Kaubisch, Amanda Weyerbacher, Sandy Yi, William Tong, Rebecca Sowers, Mithat Gonen, Eileen O'reilly, Nancy Kemeny, David I Ilson, Leonard B Saltz, Robert G Maki, David P Kelsen, Gary K Schwartz. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar; 23(9):1875-84. doi: 10.1200/jco.2005.03.116. [PMID: 15699481]
  • Adrian M Senderowicz. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques. 2005; 63(?):183-206. doi: 10.1007/3-7643-7414-4_8. [PMID: 16265881]
  • Sudhir B Kondapaka, Maryjane Zarnowski, Dena R Yver, Edward A Sausville, Samuel W Cushman. 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Nov; 10(21):7192-8. doi: 10.1158/1078-0432.ccr-04-0772. [PMID: 15534092]
  • Alex Sparreboom, Huachen Chen, Milin R Acharya, Adrian M Senderowicz, Richard A Messmann, Takashi Kuwabara, David J Venzon, Anthony J Murgo, Donna Headlee, Edward A Sausville, William D Figg. Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Oct; 10(20):6840-6. doi: 10.1158/1078-0432.ccr-04-0805. [PMID: 15501960]
  • Nhu-An Pham, James W Jacobberger, Aaron D Schimmer, Pinjiang Cao, Marcella Gronda, David W Hedley. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Molecular cancer therapeutics. 2004 Oct; 3(10):1239-48. doi: NULL. [PMID: 15486191]
  • Brian I Rini, Vivian Weinberg, Vanessa Shaw, Janet Scott, Robert Bok, John W Park, Eric J Small. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004 Jul; 101(1):90-5. doi: 10.1002/cncr.20313. [PMID: 15221993]
  • Adrian M Senderowicz. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer chemotherapy and pharmacology. 2003 Jul; 52 Suppl 1(?):S61-73. doi: 10.1007/s00280-003-0624-x. [PMID: 12819936]
  • Eiji Okubo, John M Lehman, Thomas D Friedrich. Negative regulation of mitotic promoting factor by the checkpoint kinase chk1 in simian virus 40 lytic infection. Journal of virology. 2003 Jan; 77(2):1257-67. doi: 10.1128/jvi.77.2.1257-1267.2003. [PMID: 12502843]
  • Alan Eastman, Ethan A Kohn, Mary Kay Brown, Joerg Rathman, Mark Livingstone, David H Blank, Gordon W Gribble. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Molecular cancer therapeutics. 2002 Oct; 1(12):1067-78. doi: . [PMID: 12481430]
  • Adrian M Senderowicz. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematology/oncology clinics of North America. 2002 Oct; 16(5):1229-53. doi: 10.1016/s0889-8588(02)00049-7. [PMID: 12512390]
  • Thomas S Lin, Orion M Howard, Donna S Neuberg, Helen H Kim, Margaret A Shipp. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leukemia & lymphoma. 2002 Apr; 43(4):793-7. doi: 10.1080/10428190290016908. [PMID: 12153166]
  • M A Hedaya, S S Daoud. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. Anticancer research. 2001 Nov; 21(6A):4005-10. doi: NULL. [PMID: 11911284]
  • J A Smith, J Cortes, R A Newman, T L Madden. Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasma. Journal of chromatography. B, Biomedical sciences and applications. 2001 Sep; 760(2):247-53. doi: 10.1016/s0378-4347(01)00276-6. [PMID: 11530983]
  • E A Krüger, W D Figg. Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Jul; 7(7):1867-72. doi: NULL. [PMID: 11448898]
  • E A Sausville, S G Arbuck, R Messmann, D Headlee, K S Bauer, R M Lush, A Murgo, W D Figg, T Lahusen, S Jaken, X Jing , M Roberge, E Fuse, T Kuwabara, A M Senderowicz. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Apr; 19(8):2319-33. doi: 10.1200/jco.2001.19.8.2319. [PMID: 11304786]
  • S Leclerc, M Garnier, R Hoessel, D Marko, J A Bibb, G L Snyder, P Greengard, J Biernat, Y Z Wu, E M Mandelkow, G Eisenbrand, L Meijer. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. The Journal of biological chemistry. 2001 Jan; 276(1):251-60. doi: 10.1074/jbc.m002466200. [PMID: 11013232]
  • K Yasoshima, T Kuwabara, E Fuse, T Kuramitu, N Kurata, H Nishiie, T Oishi, H Kobayashi, S Kobayashi. Pharmacokinetics, distribution, metabolism and excretion of. Cancer chemotherapy and pharmacology. 2001; 47(2):106-12. doi: 10.1007/s002800000213. [PMID: 11269735]
  • A M Senderowicz. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia. 2001 Jan; 15(1):1-9. doi: 10.1038/sj.leu.2401994. [PMID: 11243375]
  • N Kurata, S Imabeppu, M Nitoh, H Kobayashi, T Kuwabara, S Kobayashi. The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. The Journal of pharmacy and pharmacology. 2000 Nov; 52(11):1327-35. doi: 10.1211/0022357001777478. [PMID: 11186240]
  • K S Bauer, R M Lush, M A Rudek, C Shih, E Sausville, W D Figg. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomedical chromatography : BMC. 2000 Aug; 14(5):338-43. doi: 10.1002/1099-0801(200008)14:5<338::aid-bmc993>3.0.co;2-6. [PMID: 10960835]
  • E Fuse, A Hashimoto, N Sato, H Tanii, T Kuwabara, S Kobayashi, Y Sugiyama. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. Pharmaceutical research. 2000 May; 17(5):553-64. doi: 10.1023/a:1007512832006. [PMID: 10888307]
  • A M Senderowicz, E A Sausville. Preclinical and clinical development of cyclin-dependent kinase modulators. Journal of the National Cancer Institute. 2000 Mar; 92(5):376-87. doi: 10.1093/jnci/92.5.376. [PMID: 10699068]
  • S Aono, S Nakagawa, A B Reynolds, M Takeichi. p120(ctn) acts as an inhibitory regulator of cadherin function in colon carcinoma cells. The Journal of cell biology. 1999 May; 145(3):551-62. doi: 10.1083/jcb.145.3.551. [PMID: 10225956]
  • E Fuse, H Tanii, K Takai, K Asanome, N Kurata, H Kobayashi, T Kuwabara, S Kobayashi, Y Sugiyama. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer research. 1999 Mar; 59(5):1054-60. doi: NULL. [PMID: 10070963]
  • N Kurata, T Kuwabara, H Tanii, E Fuse, T Akiyama, S Akinaga, H Kobayashi, K Yamaguchi, S Kobayashi. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer chemotherapy and pharmacology. 1999; 44(1):12-8. doi: 10.1007/s002800050939. [PMID: 10367744]
  • H Fukumoto, T Tamura, Y Kamiya, J Usuda, T Suzuki, F Kanzawa, H J Kuh, Y Ohe, N Saijo, K Nishio. Activation-induced apoptosis of peripheral lymphocytes treated with 7-hydroxystaurosporine, UCN-01. Investigational new drugs. 1999; 17(4):335-41. doi: 10.1023/a:1006374118879. [PMID: 10759401]
  • A Gescher. Analogs of staurosporine: potential anticancer drugs?. General pharmacology. 1998 Nov; 31(5):721-8. doi: 10.1016/s0306-3623(98)00069-x. [PMID: 9809468]
  • E Fuse, H Tanii, N Kurata, H Kobayashi, Y Shimada, T Tamura, Y Sasaki, Y Tanigawara, R D Lush, D Headlee, W D Figg, S G Arbuck, A M Senderowicz, E A Sausville, S Akinaga, T Kuwabara, S Kobayashi. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer research. 1998 Aug; 58(15):3248-53. doi: NULL. [PMID: 9699650]
  • N Kurata, T Kuramitsu, H Tanii, E Fuse, T Kuwabara, H Kobayashi, S Kobayashi. Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01, in human plasma or urine. Journal of chromatography. B, Biomedical sciences and applications. 1998 Apr; 708(1-2):223-7. doi: 10.1016/s0378-4347(97)00642-7. [PMID: 9653966]
  • E A Sausville, R D Lush, D Headlee, A C Smith, W D Figg, S G Arbuck, A M Senderowicz, E Fuse, H Tanii, T Kuwabara, S Kobayashi. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer chemotherapy and pharmacology. 1998; 42 Suppl(?):S54-9. doi: 10.1007/s002800051080. [PMID: 9750030]
  • G M Sommers, A A Alfieri. Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model. Cancer investigation. 1998; 16(7):462-70. doi: 10.3109/07357909809011700. [PMID: 9774953]
  • D L Hill, K F Tillery, L M Rose, C F Posey. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Cancer chemotherapy and pharmacology. 1994; 35(1):89-92. doi: 10.1007/bf00686290. [PMID: 7987983]